









Markets
/
Stocks
/
nasdaq-rprx
/

Royalty Pharma PLC

RPRX

47.030USD

+1.460+3.20%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

16.50BMarket Cap

26.22P/E TTM



Royalty Pharma PLC

47.030

+1.460+3.20%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Royalty Pharma PLC

Currency: USD Updated: 2026-03-25

Key Insights

Royalty Pharma PLC's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 5 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.99.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Royalty Pharma PLC's Score

Industry at a Glance

Industry Ranking

5 / 157

Overall Ranking

31 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Royalty Pharma PLC Highlights

StrengthsRisks

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 43.83%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 43.83%.

Overvalued

The company’s latest PE is 26.22, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 352.97M shares, decreasing 1.01% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 3.28K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

51.986

Target Price

+13.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Royalty Pharma PLC is 8.61, ranking 38 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 621.99M, representing a year-over-year increase of 4.78%, while its net profit experienced a year-over-year increase of 2.88%.

Score

Industry at a Glance

Previous score

8.61

Change



Financials

5.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Royalty Pharma PLC's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Royalty Pharma PLC is 7.60, ranking 57 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 26.22, which is 1436.52% below the recent high of 402.86 and 63.76% above the recent low of 9.50.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 5/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Royalty Pharma PLC is 8.40, ranking 37 out of 157 in the Pharmaceuticals industry. The average price target is 45.00, with a high of 56.00 and a low of 34.67.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

51.986

Target Price

+13.98%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Royalty Pharma PLC

RPRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Royalty Pharma PLC is 9.12, ranking 8 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 48.35 and the support level at 45.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.99

Change

2.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.265

Neutral

RSI(14)

64.148

Neutral

STOCH(KDJ)(9,3,3)

69.992

Buy

ATR(14)

0.889

High Vlolatility

CCI(14)

168.473

Buy

Williams %R

2.128

Overbought

TRIX(12,20)

0.114

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

45.820

Buy

MA10

45.862

Buy

MA20

46.108

Buy

MA50

44.055

Buy

MA100

41.589

Buy

MA200

38.833

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Royalty Pharma PLC is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 82.61%, representing a quarter-over-quarter decrease of 1.26%. The largest institutional shareholder is Baillie Gifford, holding a total of 17.01M shares, representing 3.97% of shares outstanding, with 24.82% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Morgan Stanley Investment Management Inc. (US)

36.47M

+1.68%

Capital International Investors

27.21M

+24.37%

Nogra Group Sicaf SIF S.A.

29.93M

-16.88%

Fidelity Management & Research Company LLC

23.00M

-34.86%

BlackRock Institutional Trust Company, N.A.

17.26M

+2.30%

Baillie Gifford & Co.

Star Investors

17.37M

-3.60%

Swedbank Robur Fonder AB

12.20M

+0.35%

Adage Capital Management, L.P.

11.97M

+99.43%

State Street Investment Management (US)

10.27M

+0.76%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Royalty Pharma PLC is 9.15, ranking 16 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Royalty Pharma PLC’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.